biologics drug discovery

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

read more

Pin It on Pinterest